- Home
- PFD vs PLX Comparison
PFD vs PLX Comparison
Compare PFD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- PLX
- Stock Information
- Founded
- PFD 1990
- PLX 1993
- Country
- PFD United States
- PLX United States
- Employees
- PFD N/A
- PLX N/A
- Industry
- PFD Investment Managers
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFD Finance
- PLX Health Care
- Exchange
- PFD Nasdaq
- PLX Nasdaq
- Market Cap
- PFD 144.5M
- PLX 160.2M
- IPO Year
- PFD N/A
- PLX 1998
- Fundamental
- Price
- PFD $11.03
- PLX $1.55
- Analyst Decision
- PFD
- PLX Strong Buy
- Analyst Count
- PFD 0
- PLX 1
- Target Price
- PFD N/A
- PLX $15.00
- AVG Volume (30 Days)
- PFD 33.2K
- PLX 1.4M
- Earning Date
- PFD 01-01-0001
- PLX 05-09-2025
- Dividend Yield
- PFD 6.30%
- PLX N/A
- EPS Growth
- PFD N/A
- PLX N/A
- EPS
- PFD N/A
- PLX 0.05
- Revenue
- PFD N/A
- PLX $59,764,000.00
- Revenue This Year
- PFD N/A
- PLX $65.02
- Revenue Next Year
- PFD N/A
- PLX $57.34
- P/E Ratio
- PFD N/A
- PLX $32.18
- Revenue Growth
- PFD N/A
- PLX 0.18
- 52 Week Low
- PFD $8.53
- PLX $0.82
- 52 Week High
- PFD $11.18
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- PFD 51.79
- PLX 30.03
- Support Level
- PFD $10.93
- PLX $1.54
- Resistance Level
- PFD $11.09
- PLX $1.79
- Average True Range (ATR)
- PFD 0.10
- PLX 0.11
- MACD
- PFD -0.01
- PLX -0.02
- Stochastic Oscillator
- PFD 47.22
- PLX 27.27
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.